This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More
SELL NOW!

10 Best Healthcare & Biotech ETFs for 2014

Top-Rated ETFs

Top Healthcare/Biotech ETFs as of 3/31/14

Fund NameGet InfoOverall RatingRisk Grade
iShares US Medical Devices ETFIHIA+B-
SPDR S&P Health Care Services ETFXHSAB-
Health Care Select Sector SPDRXLVA-C+
iShares US Pharmaceuticals ETFIHEA-C+
Vanguard HealthCare Index ETFVHTA-C+
iShares US Healthcare ETFIYHA-C+
iShares Global HealthcareIXJB+C+
SPDR SP Intl Health Care ETFIRYB+C+
iShares US HealthCare Providers ETFIHFB+C+
First Trust Health Care AlphaDEXFXHB+C+

Source: TSC Ratings

Access our ETF Research Center

TheStreet Ratings' model ranks the risk-adjusted returns on all ETFs on a monthly basis.

The 10 healthcare and biotech ETFs (listed above) are ranked highest by TheStreet Ratings' methodology.

Best ETFs for 2014

ETF Investing Center

Healthcare & Biotech ETFs

Article
Investors say Johnson & Johnson's earnings beat will take the Dow and the biotech sector higher today.
4/15/14 11:04AM
Article
TheStreet highlights 3 stocks pushing the drugs industry lower today.
4/11/14 1:02PM
Article
The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a coalition of private employers, insurance companies and the government focused on fair drug pricing. But first, Express wants Gilead to cut the price of Sovaldi or be frozen out when competing hepatitis C therapies are approved later this year and next, according to a Bloomberg report.
4/8/14 11:23AM
Article
TheStreet highlights 3 stocks pushing the drugs industry lower today.
4/7/14 1:02PM
Article
TheStreet highlights 3 stocks pushing the drugs industry lower today.
4/1/14 1:03PM
Article
Biotech stocks continue to melt down. I know, broken record, but like a car wreck, it's hard not to look.
3/28/14 4:16PM
Article
Sector facing a key support level after 15% pullback from all-time high.
3/26/14 5:01PM
Article
Improving economy and falling employment are fueling the surprising rally.
3/17/14 6:04AM
Article
TheStreet highlights 3 stocks pushing the drugs industry higher today.
3/6/14 12:02PM
Article
One should at least question the reasons behind the super-sized confidence in certain assets.
2/28/14 12:36PM

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs